
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care has demonstrated promising financial performance, achieving revenue estimates of $1.111 million for 2026 and $1.229 million for 2027, slightly above prior expectations. The company is expected to return to positive new patient start growth in the U.S. by 2026, driven by increasing adoption of the innovative Mobi pump and improved access through pharmacy channels. Notably, Tandem realized a revenue beat of approximately $14 million, primarily attributed to strong U.S. market performance and successful pricing strategies linked to pharmacy penetration.
Bears say
Tandem Diabetes Care has experienced substantial operating losses since its inception, raising concerns about its ability to achieve sustained profitability. Projections indicate a potential decline in new patient starts within the U.S. diabetes pump market, coupled with risks from competitive pressures and challenges in securing favorable pharmacy channel contracts, which may hinder the company's growth. Despite exceeding shipment estimates, a year-over-year decrease in U.S. pump shipments and lower profit margins compared to its peers further contribute to the negative outlook on the company's financial health.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares